NCT03284957 2025-11-24
AMEERA-1
Sanofi
Phase 1/2 Terminated
Clinical Trials
14 trialsNCT03535506 2025-09-26
WI223281
Georgetown University
Phase 2 Terminated
NCT04478266 2025-09-11
AMEERA-5
Sanofi
Phase 3 Terminated
NCT04256941 2024-12-27
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04060862 2024-11-08
IPATunity150
Hoffmann-La Roche
Phase 1 Terminated
NCT04129151 2024-08-01
Palbociclib + Ganitumab In Ewing Sarcoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03386929 2023-12-18
SPRING
Worldwide Innovative Network Association
Phase 1/2 Terminated
NCT02907918 2021-09-29
PALTAN
Washington University School of Medicine
Phase 2 Terminated
NCT01823835 2021-06-18
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Genentech, Inc.
Phase 1/2 Terminated
NCT02349633 2021-06-10
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
Pfizer
Phase 1/2 Terminated
NCT02255461 2021-03-02
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Pediatric Brain Tumor Consortium
Phase 1 Terminated
NCT02774681 2020-04-14
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
Northwestern University
Phase 2 Terminated
NCT02334527 2018-11-16
Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT01227434 2015-07-17
PD0332991
University of California, San Francisco
Phase 2 Terminated